Diligence memo · auto-generated · as of July 2, 2026
SpyGlassPharma, Inc.
SpyGlassPharma, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
SpyGlassPharma, Inc. operates in Other Health Care, based in ALISO VIEJO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
SpyGlassPharma, Inc. has raised $135M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $75M on 2025-05-30.
Most recent recorded round closed around 2025-05-30.
Valuation (modeled)modeled
Provath models SpyGlassPharma, Inc. at approximately $485M (range $273M–$650M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.14× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 13 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 97% of Other Health Care peers (5377 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: RESTOR3D, Inc., ByHeart, Inc., VantAI Holdings, Inc., BioIntelliSense, Inc., ObjectiveHealth, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.